OR WAIT 15 SECS
Celltrion announced that its Remicade biosimilar, Rensima, could save France, Italy, and the UK up to €336 million in costs to treat Crohn’s disease.
Celltrion Healthcare announced on Feb. 19, 2015 data findings that claim Remsima (CT-P13) could save France, Italy, and the UK up to €336 million ($380 million USD), when compared in three different price discount scenarios. Remsima, which is a biosimilar monoclonal antibody (mAb) of Janssen’s Remicade (infliximab), is used to treat patients with Crohn’s disease (CD). Studies that have looked into long-term treatments and the healthcare system have found that the use of biosimilar mAbs could result in cost savings, according to a press release.
Remsima is an anti-tumor necrosis factor mAb that reduces inflammation in patients with CD. Clinical trials have demonstrated comparability of Remsima to Remicade in terms of quality, safety, and efficacy.
“The data presented today show the clear cost savings that could be achieved by introducing Remsima for the treatment of Crohn’s disease. Remsima may offer physicians an alternative to other anti-tumor necrosis factor treatments. The savings with Remsima will help more patients have access to this treatment, and may mean they can receive it earlier in their disease,” said Dr. Alex Kudrin, vice-president at Celltrion, in a press release.
In August 2014, Celltrion filed an FDA application for approval of Remsima as a biosimilar to Remicade. The application was the first 351(k) biosimilar mAb application to be filed in the US, according to a press release.